BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

$70.55

+0.69 (+0.99%)

(As of 09/17/2024 ET)

BioMarin Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 23 Analyst Ratings

Based on 23 Wall Street analysts who have issued ratings for BioMarin Pharmaceutical in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 8 have given a hold rating, 14 have given a buy rating, and 1 has given a strong buy rating for BMRN.

Consensus Price Target

$99.90
41.60% Upside

High Forecast	$122.00
Average Forecast	$99.90
Low Forecast	$72.00

According to the 23 analysts' twelve-month price targets for BioMarin Pharmaceutical, the average price target is $99.90. The highest price target for BMRN is $122.00, while the lowest price target for BMRN is $72.00. The average price target represents a forecasted upside of 41.60% from the current price of $70.55.

Type	Current Forecast 9/18/23 to 9/17/24	1 Month Ago 8/19/23 to 8/18/24	3 Months Ago 6/20/23 to 6/19/24	1 Year Ago 9/18/22 to 9/18/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	12 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)
Hold	8 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$99.90	$103.63	$106.11	$115.62
Forecasted Upside	41.60% Upside	24.16% Upside	25.73% Upside	25.41% Upside

Why Are Buffett, Bezos, and Musk Fleeing Tech? Here's What To Do Now... (Ad)

The financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumping their tech stocks at a pace we've never seen before. What do they know that's pushing them out? One that Fortune is calling:"The Great Cash Out".

Click here to get the details now.

BMRN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMRN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioMarin Pharmaceutical Stock vs. The Competition

Type	BioMarin Pharmaceutical	Medical Companies	S&P 500
Consensus Rating Score	2.70	2.77	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	42.21% Upside	985.39% Upside	7.41% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Scotiabank 5 of 5 stars		Lower Target	Sector Perform ➝ Sector Perform	$95.00 ➝ $78.00	+9.52%
9/17/2024	Wells Fargo & Company 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$115.00 ➝ $90.00	+27.08%
9/17/2024	Truist Financial 1 of 5 stars		Lower Target	Buy ➝ Buy	$118.00 ➝ $90.00	+27.08%
9/17/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform ➝ Sector Perform	$100.00 ➝ $85.00	+22.64%
9/17/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$115.00 ➝ $87.00	+24.53%
9/17/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$130.00 ➝ $115.00	+64.61%
Is A Starlink IPO Coming In 2024? (Ad) He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! And now, Elon could be set to do it for the third and final time… with what might be his biggest breakthrough yet. And for the first time ever, you have the rare chance to profit BEFORE the upcoming IPO. Click here now for the urgent details on this hidden play.
9/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Pickering Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$116.00 ➝ $90.00	+28.83%
9/13/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold ➝ Hold	$93.00 ➝ $93.00	+10.15%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$110.00 ➝ $110.00	+31.14%
9/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$111.00 ➝ $120.00	+38.26%
9/5/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$107.00 ➝ $122.00	+37.67%
8/30/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$125.00 ➝ $120.00	+38.15%
8/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$111.00 ➝ $110.00	+36.70%
8/6/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$113.00 ➝ $115.00	+42.91%
5/17/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Allen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/17/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Neutral	$104.00 ➝ $72.00	-6.46%
4/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$115.00 ➝ $112.00	+37.61%
4/25/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$94.00 ➝ $91.00	+10.75%
11/3/2023	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$102.00 ➝ $100.00	+25.52%
11/2/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$78.00	-2.10%
9/28/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
9/18/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$120.00	+36.12%
9/13/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$110.00	+19.40%
6/30/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
4/27/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains
2/28/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$110.00 ➝ $127.00	+23.01%
2/22/2023	Avian Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform
2/22/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
2/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$122.00 ➝ $130.00	+15.21%
11/29/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$100.00 ➝ $120.00	+21.63%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:46 PM ET.

BMRN Forecast - Frequently Asked Questions

What is BioMarin Pharmaceutical's forecast for 2024?: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for BioMarin Pharmaceutical is $99.90, with a high forecast of $122.00 and a low forecast of $72.00.
Should I buy or sell BioMarin Pharmaceutical stock right now?: 23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 8 hold ratings, 14 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMRN shares.
Does BioMarin Pharmaceutical's stock price have much upside?: According to analysts, BioMarin Pharmaceutical's stock has a predicted upside of 27.16% based on their 12-month stock forecasts.
Has BioMarin Pharmaceutical been upgraded by Wall Street analysts recently?: Over the previous 90 days, BioMarin Pharmaceutical's stock had 2 upgrades by analysts.
What analysts cover BioMarin Pharmaceutical?: BioMarin Pharmaceutical has been rated by research analysts at Bank of America, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Evercore ISI, JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, TD Cowen, Truist Financial, Wells Fargo & Company, and William Blair in the past 90 days.
Do Wall Street analysts like BioMarin Pharmaceutical more than its competitors?: Analysts like BioMarin Pharmaceutical less than other "medical" companies. The consensus rating score for BioMarin Pharmaceutical is 2.70 while the average consensus rating score for "medical" companies is 2.77. Learn more on how BMRN compares to other companies.